## **MINUTES**

## PCF OVERSIGHT BOARD

September 7, 2017

## OUR LADY OF THE LAKE REGIONAL MEDICAL CENTER HEROMAN BOARD ROOM BATON ROUGE, LA

Mr. Clark Cossé, Chairman, convened the meeting of the Patient's Compensation Fund Oversight Board at 6:30 PM on Thursday, September 7, 2017.

The following Board members were in attendance:

Mr. Clark Cossé, Chairman

Dr. Christopher Foret

Mr. James Hritz

Dr. Patrick Breaux

Dr. Lesley Meng

Mr. Manuel DePascual

Mr. Kent Guidry

Mr. Marcus Naquin

Others present:

Mr. Ken Schnauder

Ms. Betty Patrick

Mr. Matt Padberg

Ms. Barbara Woodard

Mr. David Woolridge

Mr. Larry Warren

Ms. Shelly Fowler

Mr. Ward Blackwell

Mr. Cossé called the meeting to order and asked the record to reflect eight Board members were in attendance and a quorum was present. Mr. Cossé then welcomed the guests to the meeting and asked all present to introduce themselves.

Mr. Cossé asked for public comments or questions. No public comments were made.

Mr. Cossé called for the approval of the August 3, 2017 minutes. Mr. Guidry moved for the minutes to be adopted and Mr. Naquin seconded the motion; by verbal vote, the minutes were adopted with no dissenting votes.

Mr. Cossé called for the quarterly investment update. Mr. Matt Padberg of Cardinal Investment Advisors provided the Board with a detailed quarterly report and portfolio update. Mr. Padberg advised the PCF's overall portfolio outperformed the benchmark by 10 basis points for the quarter and fixed income and equities outperformed their relative benchmarks for the quarter. He advised the PCF was in the process of transitioning the commodity portion of the portfolio into the new Emerging Market Debt (EMD) and equities portions over a 6-month period and believed with the sharp increase in oil prices over the last month it may be a good idea to liquidate the commodities now instead of risking downward volatility over the next 4 months. After some discussion, Mr. Guidry moved to liquidate the commodities as Cardinal deemed appropriate and hold in cash, transitioning the cash as scheduled into the EMD and equities over the next 4 months. Mr. DePascual seconded the motion; by verbal vote, the motion was approved with no dissenting votes.

PCFOB Minutes September 7, 2017

Mr. Cossé called for discussion on the Board Officer Committee vacancy. Mr. Schnauder reminded the Board that Dr. Van Culotta had resigned at the end of the August 2017 meeting and that, as Dr. Culotta had served as Vice-Chairman, his vacancy would need to be filled. After some discussion, Dr. Breaux moved to elect Dr. Christopher Foret the new Vice-Chairman. Mr. DePascual seconded the motion; by verbal vote, Dr. Foret was elected the new PCF Oversight Board Vice-Chairman.

Mr. Cossé called for the financial reports. Ms. Woodard informed the Board the Fund balance for the fiscal year to date was approximately \$1,053,809,241, the total net collected in surcharge payments to date was approximately \$18,450,377 and the total net filing fees collected to date were \$52,000. She advised the reported investment income through July was \$2,136,195, the total operating expenses to date were \$907,840, and the claims expenses to date were \$17,237,292. There were no questions asked and no public comments made.

Mr. Cossé asked for the claims report. Mr. Schnauder informed the Board for the month of August there were 82 panels filed, 128 panels closed, 91 claims opened and 121 claims closed, ending the month with total pending claims count of 4,557. Mr. Schnauder advised \$67,874 in judicial interest was paid for the month and \$235,882 in legal fees and expenses were paid. Mr. Schnauder presented 30 claims for settlement approval for the month in the amount of \$9,798,953. There were no questions asked and no public comments made.

Mr. Cossé asked if there were any questions or comments from the public. There were none.

Mr. Cossé thanked the guests for attending the meeting. Dr. Foret then made a motion for the Board to move into Executive Session; Dr. Meng seconded the motion. The verbal vote was unanimous and the Board moved into Executive Session to discuss matters of litigation.

Mr. Clark R. Cossé III, J.D., Chairman

ets, a

Date